Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 1 de 1
1.
J Alzheimers Dis ; 66(1): 289-296, 2018.
Article En | MEDLINE | ID: mdl-30248050

BACKGROUND: High-density lipoprotein (HDL) containing apolipoprotein A-I is associated with the pathogenesis of Alzheimer's disease (AD). HDL particle size is modified in the presence of pathological conditions, while the significance of the HDL particle size remains controversial. OBJECTIVE: The aim of this study was to investigate the HDL lipoprotein subclasses in mild cognitive impairment (MCI) and AD. METHODS: This cross-sectional study included 20 AD patients, 17 MCI patients, and 17 age-matched controls without cognitive impairment, selected from the database of the Study of Outcome and aPolipoproteins in Dementia (STOP-Dementia) registry. The diagnoses of AD and MCI were performed by expert neurologists according to the Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition criteria. Serum HDL subclasses were measured by electrophoretic separation of lipoproteins using the Lipoprint System. The neutrophil-lymphocyte ratio (NLR), a marker of inflammation, was calculated by dividing the neutrophil count by the lymphocyte count. RESULTS: Small-sized HDL particle levels in the MCI group were significantly higher than in the control group, although there was no difference in serum HDL-cholesterol levels between MCI and control groups. NLR in the MCI group was higher than in the control group, but this difference was non-significant (p = 0.09). There was no difference in HDL subclasses or NLR between the AD and control groups. CONCLUSION: These findings suggest that HDL subclasses might be associated with the development of MCI.


Apolipoproteins/blood , Cognitive Dysfunction/blood , Cognitive Dysfunction/diagnostic imaging , Dementia/blood , Dementia/diagnostic imaging , Lipoproteins, HDL/blood , Aged , Aged, 80 and over , Biomarkers/blood , Cognitive Dysfunction/psychology , Cross-Sectional Studies , Dementia/psychology , Female , Humans , Male , Treatment Outcome
...